Evofem Biosciences, Inc.
OTC:EVFM
0.07 (USD) • At close November 17, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 19.363 | 18.218 | 16.837 | 8.244 | 0.446 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 |
| Cost of Revenue
| 3.834 | 6.512 | 4.415 | 4.055 | 1.649 | 0.905 | 0.262 | 0.244 | 0.069 | 0.058 | 0.018 | 0.072 | 0.1 |
| Gross Profit
| 15.529 | 11.706 | 12.422 | 4.189 | -1.203 | -0.905 | -0.262 | -0.244 | -0.069 | -0.058 | -0.018 | -0.072 | 0 |
| Gross Profit Ratio
| 0.802 | 0.643 | 0.738 | 0.508 | -2.697 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 1.845 | 2.939 | 25.032 | 33.129 | 17.05 | 22.23 | 43.415 | 23.539 | 6.579 | 34.41 | 5.175 | 11.448 | 3.249 |
| General & Administrative Expenses
| 11.565 | 14.95 | 27.563 | 24.709 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 9.176 | 11.664 | 43.951 | 113.152 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 20.741 | 26.614 | 71.514 | 137.861 | 85.371 | 29.607 | 33.965 | 11.904 | 5.395 | 7.581 | 4.399 | 2.903 | 2.468 |
| Other Expenses
| 0.619 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 23.205 | 29.553 | 96.546 | 170.99 | 102.421 | 51.837 | 77.38 | 35.443 | 11.973 | 41.991 | 9.573 | 14.35 | 5.717 |
| Operating Income
| -7.676 | -17.847 | -84.124 | -166.801 | -103.624 | -52.742 | -77.642 | -35.687 | -12.042 | -42.049 | -9.591 | -14.423 | -5.741 |
| Operating Income Ratio
| -0.396 | -0.98 | -4.996 | -20.233 | -232.341 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -57.41 |
| Total Other Income Expenses Net
| -1.184 | 70.843 | 7.47 | -38.374 | -38.681 | -27.287 | -48.068 | -69.615 | -0.976 | -1.108 | -1.228 | -0.594 | -2.087 |
| Income Before Tax
| -8.86 | 52.996 | -76.654 | -205.175 | -142.305 | -80.029 | -125.71 | -105.302 | -13.019 | -43.157 | -10.819 | -15.016 | -7.828 |
| Income Before Tax Ratio
| -0.458 | 2.909 | -4.553 | -24.888 | -319.07 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -78.276 |
| Income Tax Expense
| 0 | 0.017 | 0.044 | 0.017 | 0.004 | 0.004 | 0.002 | 0.003 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -8.86 | 52.979 | -76.698 | -205.192 | -142.309 | -80.033 | -125.712 | -105.305 | -13.019 | -43.157 | -10.819 | -15.016 | -7.828 |
| Net Income Ratio
| -0.458 | 2.908 | -4.555 | -24.89 | -319.078 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -78.276 |
| EPS
| -0.092 | 10.36 | -164.59 | -2,938.96 | -3,973.23 | -3,730.27 | -10,763.01 | -85,613.82 | -10,612.22 | -35,449.44 | -8,690.15 | -11,798.92 | -6,150.5 |
| EPS Diluted
| -0.092 | 0.051 | -164.59 | -2,938.96 | -3,973.23 | -3,730.27 | -10,763.01 | -85,613.82 | -10,612.22 | -35,449.44 | -8,690.15 | -11,798.92 | -6,150.5 |
| EBITDA
| -6.92 | -16.066 | -82.078 | -165.778 | -141.124 | -79.124 | -125.448 | -105.058 | -11.914 | -41.965 | -10.427 | -14.887 | -6.767 |
| EBITDA Ratio
| -0.357 | -0.882 | -4.875 | -20.109 | -316.422 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -67.674 |